Palabras clave
Diagnóstico
Manejo de la Enfermedad
Cuidados Posteriores Monkeypox
diagnosis
Patient Care Management
Patient Care
Cómo citar
Resumen
La viruela símica (VS) es una zoonosis causada por un virus ADN bicatenario del género Orthopoxvirus. Existen dos cepas del virus de la viruela símica: la cepa de la cuenca del Congo (África Central) y la cepa de África Occidental. El objetivo de este documento es informar los aspectos generales que deben conocer los profesionales de salud, equipos de atención y otras instancias responsables de la planeación de los servicios. Se consultaron las páginas web de organismos gubernamentales nacionales e internacionales y literatura científica para sintetizar narrativamente la información de interés. Los temas abordados comprenden: epidemiología, transmisión, características clínicas, definición y confirmación de caso, vigilancia epidemiológica, medidas de bioseguridad, tratamiento y vacunas. Por otro lado, también se brindan orientaciones sobre el manejo clínico, atención a la salud mental y consideraciones para el cuidado en el hogar y la comunidad.
Citas
Organización Panamericana de Salud. Alerta Epidemiológica Viruela símica en países no endémicos. www.paho.org. 2022;
Instituto Nacional de Salud. COMUNICADO TÉCNICO No2 - 27 de mayo de 2022 CONFIRMACIÓN DE CASOS DE VIRUELA SÍMICA ( VIRUELA DEL MONO , MONKEYPOX ) EN EL MUNDO. Bogotá D.C.; 2022.
Centro de Control y Prevención de Enfermedades (CDC). Viruela del Simio. Centro de Control y Prevención de Enfermedades (CDC). 2022.
Isaacs ASN. Viruela del simio. www.uptodate.com. 2022;
Ministerio de Salud y Protección Social. ¿Qué sabemos de la viruela símica? Boletin de prensa 20 de mayo 2022. 2022.
Pan American Health Organization, World Health Organization. Weekly Situation Report on Monkeypox Multi-Country Outbreak Response - Region of the Americas. 5 August 2022. Washington, D.C; 2022.
UK Health Security Agency. Monkeypox: background information [Internet]. 2022. Available from: https://www.gov.uk/guidance/monkeypox
World Health Organization (WHO). Clinical Management and Infection Prevention and Control for Monkeypox. Interim rapid response guidance 10 June 2022. 2022. 76 p.
Russell P. Petición para evitar estigmatizar a los hombres homosexuales y bisexuales por la viruela del mono (25 mayo 2022). Medscape. 2022.
Centers for Disease Control and Prevention. Monkeypox - Clinical Recognition [Internet]. 2022. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/clinical-recognition.html
Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022. N Engl J Med [Internet]. 2022 Jul 21; Available from: https://doi.org/10.1056/NEJMoa2207323
Patel A, Bilinska J, Tam JCH, Da Silva Fontoura D, Mason CY, Daunt A, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. BMJ [Internet]. 2022 Jul 28;378:e072410. Available from: http://www.bmj.com/content/378/bmj-2022-072410.abstract
McCollum AM, Damon IK. Human Monkeypox. Clin Infect Dis. 2014 Jan;58(2):260–7.
Instituto Nacional de Salud. Comunicado técnico No1 - 19 de mayo de 2022 INFORMACIÓN GENERAL ANTE LA CONFIRMACIÓN DE CASOS. Bogotá D.C.; 2022.
Instituto Nacional de Salud. Protocolo de Vigilancia de Viruela Símica (Monkeypox) Versión: 01 [Internet]. Bogotá D. C.; 2022. Available from: https://www.ins.gov.co/Noticias/Eventosemergentes/PRO Viruela simica 30_07_2022.pdf
WHO. Surveillance, case investigation and contact tracing for monkeypox: interim guidance, 24 June 2022. 2022. Report No.: WHO/MPX/Surveillance/2022.2.
World Health Organization (WHO). Laboratory testing for the monkeypox virus Interim guidance [Internet]. 2022. Available from: https://apps.who.int/iris/rest/bitstreams/1425052/retrieve
OPS/OMS. Directrices de laboratorio para la detección y el diagnóstico de la infección por el virus de la viruela del mono. 2022.
Centers for Disease Control and Prevention. Treatment of Monkeypox [Internet]. 2021. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html
Hutson CL, Kondas A V, Mauldin MR, Doty JB, Grossi IM, N. MC, et al. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. mSphere [Internet]. 2022 Jun 2;6(1):e00927-20. Available from: https://doi.org/10.1128/mSphere.00927-20
Lanier R, Trost L, Tippin T, Lampert B, Robertson A, Foster S, et al. Development of CMX001 for the Treatment of Poxvirus Infections. Vol. 2, Viruses . 2010.
European Centre for Disease Prevention and Control. Monkeypox multi-country outbreak – 23 May 2022. [Internet]. Stockholm; 2022. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Monkeypox-multi-country-outbreak.pdf
U.S. Food and Drug Administration (FDA). Vistide (cidofovir injection) [Internet]. 2000. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/020638s003lbl.pdf
FDA. U.S. Food and Drug Administration. FDA approves the first drug with an indication for treatment of smallpox.
Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis [Internet]. 2022 Jun 2; Available from: https://doi.org/10.1016/S1473-3099(22)00228-6
EMA EMA. Tecovirimat SIGA.
Drug I, Limited HR. Register Of Innovative Drugs Products for Human Use - Active Data Protection Period Register Of Innovative Drugs Products for Human Use - Active Data Protection Period. 2023. p. 1–40.
GlobeNewswire. SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®. 2021.
Shchelkunov SN. Orthopoxvirus genes that mediate disease virulence and host tropism. Adv. Virol. 2012, 524743. 2012.
Jordan R, Leeds JM, Tyavanagimatt S, Hruby DE. Development of ST-246® for Treatment of Poxvirus Infections. Viruses. 2010 Nov;2(11):2409–35.
Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, et al. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother. 2009 May;53(5):1817–22.
Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, et al. Oral Tecovirimat for the Treatment of Smallpox. N Engl J Med. 2018 Jul;379(1):44–53.
Hill QA, Harrison LC, Padmakumar AD, Owen RG, Prasad KR, Lucas GF, et al. A fatal case of transplantation-mediated alloimmune thrombocytopenia following liver transplantation. Hematology. 2017;22(3):162–7.
Leeds JM, Fenneteau F, Gosselin NH, Mouksassi M-S, Kassir N, Marier JF, et al. Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Antimicrob Agents Chemother. 2013 Mar;57(3):1136–43.
FDA. U.S. Food and Drug Administration. Product Development Under the Animal Rule.
Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, Jones KF, et al. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother. 2010 Jun;54(6):2560–6.
Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Bolken TC, Jordan R, Jones KF, et al. Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers. Antimicrob Agents Chemother. 2012 Jul;56(7):3582–6.
Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J, et al. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother. 2008 May;52(5):1721–7.
Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF, et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother. 2012 Sep;56(9):4900–5.
CDC.Center for Disease Control and Prevention. Guidance for Tecovirimat Use Under Expanded Access Investigational New Drug Protocol during 2022 U.S. Monkeypox Cases.
World Health Organization (WHO). Vaccines and immunization for monkeypox: Interim guidance, 14 June 2022. 2022.
CDC.Center for Disease Control and Prevention. Considerations for Monkeypox Vaccination.
Reynolds MG, McCollum AM, Nguete B, Shongo Lushima R, Petersen BW. Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research. Viruses. 2017;9(12).
Bellinato F, Gisondi P, Girolomoni G. Monkeypox virus infection: what dermatologist needs to know? J Eur Acad Dermatology Venereol [Internet]. 2022 Aug 1;36(8):e656–8. Available from: https://doi.org/10.1111/jdv.18299
Centro para el Control y la Prevención de Enfermedades CDC. Isolation and Prevention Practices for People with Monkeypox. Updated August 2, 2022 [Internet]. 2022 [cited 2022 Aug 5]. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/isolation-procedures.html
UK Health Security Agency. Orientación Viruela del mono: personas infectadas que están haciendo cuarentena en casa. 2022.